Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Recipient : University of Copenhagen
Deal Size : Inapplicable
Deal Type : Inapplicable
Slow Age: Interventions to Slow Aging in Humans
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2022
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Recipient : University of Copenhagen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : University of Oxford
Deal Size : Undisclosed
Deal Type : Partnership
Details : Developing Elysium Health's proprietary algorithmic platform for epigenetic examination (APEX), and the company's biological age measure Index, Elysium Health plans to utilize the VITACOG biobank to explore the development and commercialization of novel ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 23, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : University of Oxford
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Neurology
Study Phase : Undisclosed
Recipient : Haukeland University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2021
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : Haukeland University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Recipient : University of South Alabama
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 12, 2021
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Recipient : University of South Alabama
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Neurology
Study Phase : Undisclosed
Recipient : Haukeland University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
The NO-ALS Study: a Trial of Nicotinamide/pterostilbene Supplement in ALS.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2020
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : Haukeland University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Undisclosed
Study Phase : Phase II
Recipient : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Protection From Acute Kidney Injury (AKI) With Basisâ„¢ Treatment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2020
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Recipient : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : University of Exeter
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2019
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : University of Exeter
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : University of Pennsylvania
Deal Size : Inapplicable
Deal Type : Inapplicable
Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 17, 2018
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : University of Pennsylvania
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NRPT
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
May 01, 2018
Lead Product(s) : NRPT
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Basis
Therapeutic Area : Nephrology
Study Phase : Undisclosed
Recipient : Massachusetts General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
June 05, 2017
Lead Product(s) : Basis
Therapeutic Area : Nephrology
Highest Development Status : Undisclosed
Recipient : Massachusetts General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable